ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology
News provided by
Share this article
Share this article
LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement.
Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN s development teams. ImaginAb will receive license fees and other contingent payments. No other terms were disclosed.
Após aparecer com novo namorado, Lady Gaga está feliz e saudável uol.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uol.com.br Daily Mail and Mail on Sunday newspapers.
Lady Gaga shares romantic pic with boyfriend from Inauguration Day yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Tmunity Announces Appointment of Jeffrey Leiden M.D., Ph.D. as Chairman of the Board of Directors
January 25, 2021 GMT
PHILADELPHIA (BUSINESS WIRE) Jan 25, 2021
Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the appointment of Jeffrey Leiden, M.D., Ph.D., as Non-Executive Chairman of its Board of Directors.
“I am thrilled to welcome Jeff as Chair of our board of directors as 2021 will be a transformative year for Tmunity with our continued rapid advancement of our clinical and preclinical oncology portfolio. We wanted to bring on an equally transformative leader to chair our board, a physician-scientist who is passionate about translating scientific advances into breakthrough therapies for our patients,